全文获取类型
收费全文 | 136254篇 |
免费 | 9768篇 |
国内免费 | 467篇 |
专业分类
耳鼻咽喉 | 1481篇 |
儿科学 | 3503篇 |
妇产科学 | 2450篇 |
基础医学 | 19876篇 |
口腔科学 | 2870篇 |
临床医学 | 13908篇 |
内科学 | 28553篇 |
皮肤病学 | 2364篇 |
神经病学 | 14332篇 |
特种医学 | 5600篇 |
外国民族医学 | 9篇 |
外科学 | 19296篇 |
综合类 | 1548篇 |
一般理论 | 82篇 |
预防医学 | 9937篇 |
眼科学 | 2886篇 |
药学 | 8845篇 |
中国医学 | 180篇 |
肿瘤学 | 8769篇 |
出版年
2023年 | 691篇 |
2022年 | 1272篇 |
2021年 | 2579篇 |
2020年 | 1577篇 |
2019年 | 2459篇 |
2018年 | 2993篇 |
2017年 | 2249篇 |
2016年 | 2688篇 |
2015年 | 3072篇 |
2014年 | 4050篇 |
2013年 | 5476篇 |
2012年 | 8300篇 |
2011年 | 8391篇 |
2010年 | 5035篇 |
2009年 | 4610篇 |
2008年 | 7476篇 |
2007年 | 8174篇 |
2006年 | 7691篇 |
2005年 | 7606篇 |
2004年 | 7050篇 |
2003年 | 6352篇 |
2002年 | 6360篇 |
2001年 | 2618篇 |
2000年 | 2498篇 |
1999年 | 2296篇 |
1998年 | 1584篇 |
1997年 | 1292篇 |
1996年 | 1086篇 |
1995年 | 1115篇 |
1994年 | 949篇 |
1993年 | 882篇 |
1992年 | 1671篇 |
1991年 | 1550篇 |
1990年 | 1482篇 |
1989年 | 1377篇 |
1988年 | 1272篇 |
1987年 | 1199篇 |
1986年 | 1232篇 |
1985年 | 1199篇 |
1984年 | 1015篇 |
1983年 | 865篇 |
1982年 | 799篇 |
1981年 | 689篇 |
1980年 | 582篇 |
1979年 | 779篇 |
1978年 | 641篇 |
1977年 | 558篇 |
1975年 | 500篇 |
1974年 | 566篇 |
1973年 | 542篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
23.
Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma 总被引:5,自引:0,他引:5
Measurement of health-related quality of life was integrated into a randomized trial (NMSG 4/90) comparing melphalan/prednisone to melphalan/prednisone + interferon α-2b in newly diagnosed multiple myeloma. One of the aims of the study was to assess the prognostic significance of quality-of-life scores, using the EORTC QLQ-C30 questionnaire. Univariate analysis showed a highly significant association with survival from the start of therapy for physical functioning as well as role and cognitive functioning, global quality of life, fatigue and pain. In multivariate analysis, physical functioning and W.H.O. performance status were independent prognostic factors ( P values=0.001 for both) when analysed in a Cox regression model with the somatic variables β-2 microglobulin, skeletal disease and age. The best prediction for survival from the start of therapy was obtained by combining the β-2 microglobulin and physical functioning scores in a variable consisting of three risk factor levels with an estimated median survival of 17, 29 and 49 months, respectively. At a 12 months landmark analysis, the relative risk for patients with physical functioning score 0–20 v 80–100 was 5.63 (99% CI 2.76–11.49), whereas the relative risk for patients without an objective response to chemotherapy compared to those with at least a minor response was 2.32 (99% CI 1.44–3.74). Quality-of-life assessment may be an independent and valuable addition to the known prognostic factors in multiple myeloma. 相似文献
24.
25.
26.
Human balancing of an inverted pendulum: position control by small, ballistic-like, throw and catch movements 总被引:12,自引:4,他引:8
In standing, there are small sways of the body. Our interest is to use an artificial task to illuminate the mechanisms underlying the sways and to account for changes in their size. Using the ankle musculature, subjects balanced a large inverted pendulum. The equilibrium of the pendulum is unstable and quasi-regular sway was observed like that in quiet standing. By giving full attention to minimising sway subjects could systematically reduce pendulum movement. The pendulum position, the torque generated at each ankle and the soleus and tibialis anterior EMGs were recorded. Explanations about how the human inverted pendulum is balanced usually ignore the fact that balance is maintained over a range of angles and not just at one angle. Any resting equilibrium position of the pendulum is unstable and in practice temporary; movement to a different resting equilibrium position can only be accomplished by a biphasic 'throw and catch' pattern of torque and not by an elastic mechanism. Results showed that balance was achieved by the constant repetition of a neurally generated ballistic-like biphasic pattern of torque which can control both position and sway size. A decomposition technique revealed that there was a substantial contribution to changes in torque from intrinsic mechanical ankle stiffness; however, by itself this was insufficient to maintain balance or to control position. Minimisation of sway size was caused by improvement in the accuracy of the anticipatory torque impulses. We hypothesise that examination of centre of mass and centre of pressure data for quiet standing will duplicate these results. 相似文献
27.
Regulatory properties of brain glutamate decarboxylase (GAD): the apoenzyme of GAD is present principally as the smaller of two molecular forms of GAD in brain 总被引:10,自引:0,他引:10
The apoenzyme of glutamate decarboxylase [enzyme without bound cofactor, pyridoxal 5'-phosphate (pyridoxal-P)] serves as a reservoir of inactive glutamate decarboxylase (GAD) that can be activated when additional GABA synthesis is required. We have investigated which of two molecular forms of GAD is present as apoenzyme in synaptosomes and in cortex, caudate nucleus, hippocampus, and cerebellum of rat brain. Endogenous glutamate apodecarboxylase (apoGAD) was labeled by incubating extracts of synaptosomes or punches of each region with 32P-pyridoxal-P, followed by reduction with NaBH4, to link covalently the 32P-pyridoxal-P to GAD. Proteins were separated by SDS-PAGE. Punches from all four brain regions and forebrain synaptosomes contained two forms of GAD with apparent Mrs of 63 and 65 kDa as identified by immunoblotting with four antiGAD sera. Punches and synaptosomes contained a major 32P-pyridoxal-P-labeled band with an apparent Mr of 63 kDa that was stained on immunoblots by the antiGAD serum 1440 and the monoclonal antibody GAD-6, and a minor labeled band at 65 kDa that was stained by the 1440, 6799, and K2 antisera. Synaptosomes contained remarkably few other strongly labeled proteins, but punches contained several other labeled bands. Three additional lines of evidence indicate that the labeled 63-kDa protein is apoGAD: (1) it was purified by immunoaffinity chromatography with the GAD-1 monoclonal antibody; (2) it yielded one major labeled peptide when digested with chymotrypsin, and that peptide appeared identical in peptide-mapping experiments to the labeled active-site peptide isolated from chromatographically prepared rat brain GAD; and (3) its labeling was selectively blocked by 4-deoxypyridoxine 5'-phosphate, a competitive inhibitor of the binding of pyridoxal-P to GAD.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
28.
F Elferink W J van der Vijgh W W ten Bokkel Huinink J B Vermorken I Klein B Winograd M K Knobf G Simonetti H E Gall J G McVie 《British journal of cancer》1987,56(4):479-483
Pharmacokinetics of the cis-platin analog ethylenediaminemalonatoplatinum(II) (JM-410) was studied in 28 cycles of 19 patients during the phase I study of this drug. The drug was administered intravenously by short-term (10-60 min) infusion. Doses ranged from 20 to 1,200mg m-2. JM-40 was determined in plasma ultrafiltrate and urine by HPLC. Platinum (Pt) concentrations were determined in plasma, plasma ultrafiltrate, urine and red blood cells by atomic absorption spectrometry up to 5 days after administration of the drug. Ultrafilterable Pt could be determined up to 45 days after the infusion in one patient sampled over such a long period. Pharmacokinetics of JM-40 showed a linear behaviour. The final half-life of total Pt in plasma was 4.1 +/- 0.9 days. The disposition of JM-40 was similar to that of ultrafilterable Pt in respect to t1/2 alpha (10 and 13 min), t1/2 beta (44 and 57 min), volumes of distribution Vc (11 and 121) and Vss (17 and 201), systemic clearance (256 and 223 ml min-1), renal clearance (69 and 73 ml min-1) and metabolic clearance (183 and 154 ml min-1). During the first 6 h 27 +/- 9% of the administered dose was excreted as JM-40. Cumulative platinum excretion in the urine amounted to 29 +/- 13% and 60 +/- 13% over the first 6 h, 24 h and 5 days, respectively. The uptake of platinum in red blood cells was limited, comprising only 0.24 +/- 0.12% of the administered dose. Although JM-40 and carboplatin are structurally closely related, pharmocokinetics and toxicity of JM-40 were more similar to cis-platin than to carboplatin. 相似文献
29.
P A DeSimone C A Martin C B Bacdayan J S Macdonald F J Rizzo J Engelberg 《Hospital practice (Office ed.)》1986,21(1):158, 160, 165-158, 7 passim
30.
F C Martin 《The Practitioner》1987,231(1431):848-852